Yonhap Infomax NewsHanmi Pharmaceutical has received regulatory approval to begin a Phase 2 clinical trial of its targeted melanoma drug Belvarafenib, aiming to address unmet needs in cancer treatment with a combination therapy for patients with NRAS-mutant melanoma.
#YonhapInfomax #HanmiPharmaceutical #Belvarafenib #Melanoma #ClinicalTrial #NRASMutation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99004
#YonhapInfomax #HanmiPharmaceutical #Belvarafenib #Melanoma #ClinicalTrial #NRASMutation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99004
Hanmi Pharmaceutical Initiates Phase 2 Clinical Trial for Melanoma Drug
Hanmi Pharmaceutical has received regulatory approval to begin a Phase 2 clinical trial of its targeted melanoma drug Belvarafenib, aiming to address unmet needs in cancer treatment with a combination therapy for patients with NRAS-mutant melanoma.